-
1
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell, 2011, 144(5), 646-674.
-
(2011)
Cell
, vol.144
, Issue.5
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
2
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med., 1971, 285(21), 1182-1186.
-
(1971)
N. Engl. J. Med.
, vol.285
, Issue.21
, pp. 1182-1186
-
-
Folkman, J.1
-
3
-
-
0034092011
-
Tumor angiogenesis: Past, present and the near future
-
Kerbel, R. S. Tumor angiogenesis: past, present and the near future. Carcinogenesis, 2000, 21(3), 505-515.
-
(2000)
Carcinogenesis
, vol.21
, Issue.3
, pp. 505-515
-
-
Kerbel, R.S.1
-
4
-
-
0031969264
-
Angiogenesis and tumor metastasis
-
Bruce R. Zetter. Angiogenesis and tumor metastasis. Annu. Rev. Med., 1998, 49, 407-424.
-
(1998)
Annu. Rev. Med.
, vol.49
, pp. 407-424
-
-
Bruce, R.Z.1
-
5
-
-
0030576517
-
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
-
Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86(3), 353-364.
-
(1996)
Cell
, vol.86
, Issue.3
, pp. 353-364
-
-
Hanahan, D.1
Folkman, J.2
-
6
-
-
77953257462
-
Heterogeneity of the tumor vasculature
-
Nagy, J.A.; Chang, S.H.; Shih, S.C.; Dvorak, A.M.; Dvorak, H.F. Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost., 2010, 36(3), 321-331.
-
(2010)
Semin. Thromb. Hemost.
, vol.36
, Issue.3
, pp. 321-331
-
-
Nagy, J.A.1
Chang, S.H.2
Shih, S.C.3
Dvorak, A.M.4
Dvorak, H.F.5
-
7
-
-
33645971968
-
Antiangiogenesis drug design: Multiple pathways targeting tumor vasculature
-
Zhong, H.; Bowen, J. P. Antiangiogenesis Drug Design: Multiple Pathways Targeting Tumor Vasculature. Curr. Med. Chem., 2006, 13(8), 849-862.
-
(2006)
Curr. Med. Chem.
, vol.13
, Issue.8
, pp. 849-862
-
-
Zhong, H.1
Bowen, J.P.2
-
8
-
-
0038012338
-
Angiogenesis inhibitors under study for the treatment of lung cancer
-
Shepherd, F. A.; Sridhar, S. S. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer, 2003, 41, S63-S72.
-
(2003)
Lung Cancer
, vol.41
-
-
Shepherd, F.A.1
Sridhar, S.S.2
-
10
-
-
0032907687
-
Vascular endothelial growth factor (vegf) and its receptors
-
Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J.,1999, 13(1), 9-22.
-
(1999)
FASEB J.
, vol.13
, Issue.1
, pp. 9-22
-
-
Neufeld, G.1
Cohen, T.2
Gengrinovitch, S.3
Poltorak, Z.4
-
11
-
-
0031572858
-
The crystal structure of vascular endothelial growth factor (vegf) refined to 1.93 å resolution: Multiple copy flexibility and receptor binding
-
Yv Muller, Y. A.; Christinger, H. W.; Keyt, B. A.; de Vos, A. M. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 Å resolution: multiple copy flexibility and receptor binding. Structure, 1997, 5(10), 1325-1327.
-
(1997)
Structure
, vol.5
, Issue.10
, pp. 1325-1327
-
-
Muller, Y.Y.A.1
Christinger, H.W.2
Keyt, B.A.3
De Vos, A.M.4
-
13
-
-
4143136640
-
Vascular endothelial growth factor: Basic science and clinical progress
-
Ferrara, N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocrine Rev., 2004, 25(4), 581-611.
-
(2004)
Endocrine Rev.
, vol.25
, Issue.4
, pp. 581-611
-
-
Ferrara, N.1
-
14
-
-
1642280409
-
Diffentiated human podocytes endogeously express an inhibitory isoform of vascular endothelia growth factor (vegf165b) mrna and protein
-
Cui, T.G.; R.R.; Saleem, M.; Matieson, P.W.; Gillatt,D.A.; Bates, D.O.; Harper, S.J. Diffentiated human podocytes endogeously express an inhibitory isoform of vascular endothelia growth factor (VEGF165b) mRNA and protein. Am. J. Physiol-Renal., 2004, 286(4), 767-773.
-
(2004)
Am. J. Physiol-Renal.
, vol.286
, Issue.4
, pp. 767-773
-
-
Cui, T.G.1
Saleem, M.2
Matieson, P.W.3
Gillatt, D.A.4
Bates, D.O.5
Harper, S.J.6
-
15
-
-
0026699255
-
Flt4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines
-
Pajusola K; Aprelikova O; Korhonen J; Kaipainen A; PertovaaraL; Alitalo R; Alitalo K. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res., 1992, 52(20), 5738-5743.
-
(1992)
Cancer Res.
, vol.52
, Issue.20
, pp. 5738-5743
-
-
Pajusola, K.1
Aprelikova, O.2
Korhonen, J.3
Kaipainen, A.4
Pertovaara, L.5
Alitalo, R.6
Alitalo, K.7
-
16
-
-
78650853253
-
Recent progress of small molecular vegfr inhibitors as anticancer agents
-
Xu, D.; Wang, T. L.; Sun, L. P.; You, Q. D. Recent progress of small molecular VEGFR inhibitors as anticancer agents. Mini Rev. Med. Chem., 2011, 11(1), 18-31.
-
(2011)
Mini Rev. Med. Chem.
, vol.11
, Issue.1
, pp. 18-31
-
-
Xu, D.1
Wang, T.L.2
Sun, L.P.3
You, Q.D.4
-
17
-
-
0037699954
-
The biology of vegf and its receptors
-
Ferrara, N.; Gerber, H. P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9(6), 669-676.
-
(2003)
Nat. Med.
, vol.9
, Issue.6
, pp. 669-676
-
-
Ferrara, N.1
Gerber, H.P.2
LeCouter, J.3
-
18
-
-
0034979159
-
Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis
-
Dor, Y.; Porat, R.; Keshet, E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol. Cell Physiol., 2001, 280(6), C1367-C1374.
-
(2001)
Am. J. Physiol. Cell Physiol.
, vol.280
, Issue.6
-
-
Dor, Y.1
Porat, R.2
Keshet, E.3
-
19
-
-
0031039243
-
The biology of vascular endothelial growth factor
-
Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev., 1997, 18(1), 4-25.
-
(1997)
Endocr. Rev.
, vol.18
, Issue.1
, pp. 4-25
-
-
Ferrara, N.1
Davis-Smyth, T.2
-
20
-
-
0032907687
-
Vascular endothelial growth factor (vegf) and its receptors
-
Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB. J., 1999, 13(1), 9-22.
-
(1999)
FASEB. J.
, vol.13
, Issue.1
, pp. 9-22
-
-
Neufeld, G.1
Cohen, T.2
Gengrinovitch, S.3
Poltorak, Z.4
-
21
-
-
84861539889
-
An update on the current and emerging targeted agents in metastatic colorectal cancer
-
Chu, E. An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer. Clin. Colorectal Cancer, 2011, 11(1), 1-13.
-
(2011)
Clin. Colorectal Cancer
, vol.11
, Issue.1
, pp. 1-13
-
-
Chu, E.1
-
22
-
-
22244490088
-
Identification of novel extracellular signal-regulated kinase docking domain inhibitors
-
Hancock, C. N.; Macias, A.; Lee, E. K.; Yu, S. Y. ; Mackerell, A. D., Jr.; Shapiro, P. Identification of Novel Extracellular Signal-Regulated Kinase Docking Domain Inhibitors. J. Med. Chem., 2005, 48(14), 4586-4595.
-
(2005)
J. Med. Chem.
, vol.48
, Issue.14
, pp. 4586-4595
-
-
Hancock, C.N.1
Macias, A.2
Lee, E.K.3
Yu, S.Y.4
Mackerell Jr., A.D.5
Shapiro, P.6
-
25
-
-
0030888185
-
The am and fm of calcium signalling
-
Berridge, M.J. The AM and FM of calcium signalling. Nature, 1997, 386(6627), 759-760.
-
(1997)
Nature
, vol.386
, Issue.6627
, pp. 759-760
-
-
Berridge, M.J.1
-
26
-
-
33846940789
-
Vincristine regulates the phosphorylation of the antiapoptotic protein hsp27 in breast cancer cells
-
Casado, P.; Zuazua-Villar, P.; del Valle, E.; Martinez-Campa, C.; Lazo, P. S.; Ramos, S. Vincristine regulates the phosphorylation of the antiapoptotic protein HSP27 in breast cancer cells. Cancer Lett., 2007, 247(2), 273-282.
-
(2007)
Cancer Lett.
, vol.247
, Issue.2
, pp. 273-282
-
-
Casado, P.1
Zuazua-Villar, P.2
Del Valle, E.3
Martinez-Campa, C.4
Lazo, P.S.5
Ramos, S.6
-
27
-
-
29244479188
-
Blocking tumor cell migration and invasion with biphenyl isoxazole derivative kribb3, a synthetic molecule that inhibits hsp27 phosphorylation
-
Shin, K. D.; Lee, M. Y. ; Shin, D. S.; Lee, S.; Son, K. H.; Koh, S.; Paik, Y. K.; Kwon, B. M.; Han, D. C. Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J. Biol. Chem., 2005, 280(50), 41439-41448.
-
(2005)
J. Biol. Chem.
, vol.280
, Issue.50
, pp. 41439-41448
-
-
Shin, K.D.1
Lee, M.Y.2
Shin, D.S.3
Lee, S.4
Son, K.H.5
Koh, S.6
Paik, Y.K.7
Kwon, B.M.8
Han, D.C.9
-
28
-
-
0034000699
-
Vegf receptor signal in tumor angiogenesis
-
McMahon, G. VEGF receptor signal in tumor angiogenesis. Oncologist, 2000, 5, 3-10.
-
(2000)
Oncologist
, vol.5
, pp. 3-10
-
-
McMahon, G.1
-
29
-
-
0037391673
-
Vegf blocking therapy in the treatment of cancer
-
Glade-Bender, J.; Kandel, J. J.; Yamashiro, D. J. VEGF blocking therapy in the treatment of cancer. Expert Opin. Biol. Ther., 2003, 3(2), 263-276.
-
(2003)
Expert Opin. Biol. Ther.
, vol.3
, Issue.2
, pp. 263-276
-
-
Glade-Bender, J.1
Kandel, J.J.2
Yamashiro, D.J.3
-
30
-
-
84855655264
-
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology
-
Stewart, M. W. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin. Proc., 2012, 87(1), 77-88.
-
(2012)
Mayo Clin. Proc.
, vol.87
, Issue.1
, pp. 77-88
-
-
Stewart, M.W.1
-
31
-
-
21744446220
-
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration
-
Ng, E. W. ; Adamis, A. P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol., 2005, 40(3), 352-368.
-
(2005)
Can. J. Ophthalmol.
, vol.40
, Issue.3
, pp. 352-368
-
-
Ng, E.W.1
Adamis, A.P.2
-
32
-
-
35448952213
-
Antiangiogenic agents: An update on small molecule vegfr inhibitors
-
Schenone, S.; Bondavalli, F.; Botta, M. Antiangiogenic Agents: An Update on Small Molecule VEGFR Inhibitors. Curr. Med. Chem., 2007, 14(23), 2495-2516.
-
(2007)
Curr. Med. Chem.
, vol.14
, Issue.23
, pp. 2495-2516
-
-
Schenone, S.1
Bondavalli, F.2
Botta, M.3
-
33
-
-
33646417088
-
Potent neutralization of vegf biological activities with a fully human antibody fab fragment directed against vegf receptor 2
-
Miao, H. Q.; Hu, K.; Jimenez, X.; Navarro, E.; Zhang, H.; Lu, D.; Ludwig, D. L.; Balderes, P.; Zhu, Z. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem. Biophys. Res. Commun., 2006, 345(1), 438-445.
-
(2006)
Biochem. Biophys. Res. Commun.
, vol.345
, Issue.1
, pp. 438-445
-
-
Miao, H.Q.1
Hu, K.2
Jimenez, X.3
Navarro, E.4
Zhang, H.5
Lu, D.6
Ludwig, D.L.7
Balderes, P.8
Zhu, Z.9
-
34
-
-
27944456516
-
Managing patients treated with bevacizumab combination therapy
-
Gordon, M. S.; Cunningham, D. Managing patients treated with bevacizumab combination therapy. Oncology, 2005, 69 Suppl 3, 25-33.
-
(2005)
Oncology
, vol.69
, Issue.SUPPL. 3
, pp. 25-33
-
-
Gordon, M.S.1
Cunningham, D.2
-
35
-
-
84893616814
-
Advances in targeted therapy of colorectal cancer by bavacizumab
-
Luo, C.; Ying, J. Advances in Targeted Therapy of Colorectal Cancer by Bavacizumab. Chinese General Practice, 2011, 29, 3407-3409.
-
(2011)
Chinese General Practice
, vol.29
, pp. 3407-3409
-
-
Luo, C.1
Ying, J.2
-
36
-
-
35548982639
-
Anti-plgf inhibits growth of vegf(r)-inhibitorresistant tumors without affecting healthy vessels
-
Fischer, C.; Jonckx, B.; Mazzone, M.; Zacchigna, S.; Loges, S.; Pattarini, L.; Chorianopoulos, E.; Liesenborghs, L.; Koch, M.; De Mol, M.; Autiero, M.; Wyns, S.; Plaisance, S.; Moons, L.; van Rooijen, N.; Giacca, M.; Stassen, J. M.; Dewerchin, M.; Collen, D.; Carmeliet, P. Anti-PlGF inhibits growth of VEGF(R)-inhibitorresistant tumors without affecting healthy vessels. Cell, 2007, 131(3), 463-475.
-
(2007)
Cell
, vol.131
, Issue.3
, pp. 463-475
-
-
Fischer, C.1
Jonckx, B.2
Mazzone, M.3
Zacchigna, S.4
Loges, S.5
Pattarini, L.6
Chorianopoulos, E.7
Liesenborghs, L.8
Koch, M.9
De Mol, M.10
Autiero, M.11
Wyns, S.12
Plaisance, S.13
Moons, L.14
Van Rooijen, N.15
Giacca, M.16
Stassen, J.M.17
Dewerchin, M.18
Collen, D.19
Carmeliet, P.20
more..
-
37
-
-
35548934659
-
Alphaplgf: A new kid on the antiangiogenesis block
-
Jain, R. K.; Xu, L. alphaPlGF: A new kid on the antiangiogenesis block. Cell, 2007, 131(3), 443-445.
-
(2007)
Cell
, vol.131
, Issue.3
, pp. 443-445
-
-
Jain, R.K.1
Xu, L.2
-
38
-
-
84861307333
-
Inhibition of placenta growth factor with tb-403: A novel antiangiogenic cancer therapy
-
Nielsen, D. L.; Sengelov, L. Inhibition of placenta growth factor with TB-403: A novel antiangiogenic cancer therapy. Expert Opin. Biol. Ther., 2012, 12(6), 795-804.
-
(2012)
Expert Opin. Biol. Ther.
, vol.12
, Issue.6
, pp. 795-804
-
-
Nielsen, D.L.1
Sengelov, L.2
-
39
-
-
80053041612
-
Monoclonal antibody tb-403: A first-in-human, phase i, double-blind, dose escalation study directed against placental growth factor in healthy male subjects
-
Martinsson-Niskanen, T.; Riisbro, R.; Larsson, L.; Winstedt, L.; Stenberg, Y.; Pakola, S.; Stassen, J. M.; Glazer, S. Monoclonal antibody TB-403: A first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin. Ther., 2011, 33(9), 1142-1149.
-
(2011)
Clin. Ther.
, vol.33
, Issue.9
, pp. 1142-1149
-
-
Martinsson-Niskanen, T.1
Riisbro, R.2
Larsson, L.3
Winstedt, L.4
Stenberg, Y.5
Pakola, S.6
Stassen, J.M.7
Glazer, S.8
-
40
-
-
33645095226
-
Pegaptanib a targeted anti-vegf aptamer for ocular vascular disease
-
Ng, E. W.; Shima, D. T.; Calias, P.; Cunningham, E. T., Jr.; Guyer, D. R.; Adamis, A. P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov., 2006, 5(2), 123-132.
-
(2006)
Nat. Rev. Drug Discov.
, vol.5
, Issue.2
, pp. 123-132
-
-
Ng, E.W.1
Shima, D.T.2
Calias, P.3
Cunningham Jr., E.T.4
Guyer, D.R.5
Adamis, A.P.6
-
41
-
-
33746910190
-
Pegaptanib for the treatment of age-related macular degeneration
-
Zhou, B.; Wang, B. Pegaptanib for the treatment of age-related macular degeneration. Exp. Eye Res., 2006, 83(3), 615-619.
-
(2006)
Exp. Eye Res.
, vol.83
, Issue.3
, pp. 615-619
-
-
Zhou, B.1
Wang, B.2
-
42
-
-
3242734630
-
Aptamers, intramers, and vascular endothelial growth factor
-
Waheed, N.K.;Miller, J.W. Aptamers, intramers, and vascular endothelial growth factor. Int. Ophthalmol. Clin., 2004, 44(3), 11-22.
-
(2004)
Int. Ophthalmol. Clin.
, vol.44
, Issue.3
, pp. 11-22
-
-
Waheed, N.K.1
Miller, J.W.2
-
43
-
-
67349167635
-
Discovery and development of the g-rich oligonucleotide as1411 as a novel treatment for cancer
-
Bates, P. J.; Laber, D. A.; Miller, D. M.; Thomas, S. D.; Trent, J. O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol., 2009, 86(3), 151-164.
-
(2009)
Exp. Mol. Pathol.
, vol.86
, Issue.3
, pp. 151-164
-
-
Bates, P.J.1
Laber, D.A.2
Miller, D.M.3
Thomas, S.D.4
Trent, J.O.5
-
44
-
-
77950145605
-
Aptamer-based tumor-targeted drug delivery for photodynamic therapy
-
Shieh, Y. A.; Yang, S. J.; Wei, M. F.; Shieh, M. J. Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano., 2010, 4(3), 1433-1442.
-
(2010)
ACS Nano.
, vol.4
, Issue.3
, pp. 1433-1442
-
-
Shieh, Y.A.1
Yang, S.J.2
Wei, M.F.3
Shieh, M.J.4
-
45
-
-
2542465496
-
-
Department of Health & Human Services: FDA approves Eylea for eye disorder in older people. (Accessed Nov 18
-
U.S. Food and Drug Administration, U.S. Department of Health & Human Services: FDA approves Eylea for eye disorder in older people. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm (Accessed Nov 18, 2011)
-
(2011)
U.S. Food and Drug Administration U.S
-
-
-
46
-
-
57649229413
-
Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using qsar and docking
-
Du, J.; Lei, B.; Qin, J. ; Liu, H. ; Yao, X. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. J. Mol. Graph. Model, 2009, 27(5), 642-654.
-
(2009)
J. Mol. Graph. Model
, vol.27
, Issue.5
, pp. 642-654
-
-
Du, J.1
Lei, B.2
Qin, J.3
Liu, H.4
Yao, X.5
-
47
-
-
2542465496
-
-
Department of Health & Human Services: FDA approves new treatment for rare form of thyroid cancer. (Accessed April 7
-
U.S. Food and Drug Administration, U.S. Department of Health & Human Services: FDA approves new treatment for rare form of thyroid cancer. http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm250168.htm (Accessed April 7, 2011)
-
(2011)
U.S. Food and Drug Administration U.S
-
-
-
48
-
-
57649229413
-
Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using qsar and docking
-
Du, J.; Lei, B.; Qin, J. ; Liu, H. ; Yao, X. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. J. Mol. Graph. Model, 2009, 27(5), 642-654.
-
(2009)
J. Mol. Graph. Model
, vol.27
, Issue.5
, pp. 642-654
-
-
Du, J.1
Lei, B.2
Qin, J.3
Liu, H.4
Yao, X.5
-
49
-
-
49449117755
-
Discovery of 5-[ [4-[(2,3-dimethyl-2hindazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methyl benzenesulf-onamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor
-
Cheung, M.; Kumar, R. Discovery of 5-[ [4-[(2,3-Dimethyl-2Hindazol-6-yl) methylamino]-2-pyrimidinyl]amino]-2-methyl benzenesulf-onamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor. J. Med. Chem., 2008, 51(15), 4632-4640.
-
(2008)
J. Med. Chem.
, vol.51
, Issue.15
, pp. 4632-4640
-
-
Cheung, M.1
Kumar, R.2
-
50
-
-
24944543833
-
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors
-
Dai, Y.; Guo, Y.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Ahmed, A. A.; Albert, D. H.; Arnold, L.; Arries, S. S.; Barlozzari, T.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Pease, L. J.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Wishart, N.; Davidsen, S. K.; Michaelides, M. R. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem., 2005, 48(19), 6066-6083.
-
(2005)
J. Med. Chem.
, vol.48
, Issue.19
, pp. 6066-6083
-
-
Dai, Y.1
Guo, Y.2
Frey, R.R.3
Ji, Z.4
Curtin, M.L.5
Ahmed, A.A.6
Albert, D.H.7
Arnold, L.8
Arries, S.S.9
Barlozzari, T.10
Bauch, J.L.11
Bouska, J.J.12
Bousquet, P.F.13
Cunha, G.A.14
Glaser, K.B.15
Guo, J.16
Li, J.17
Marcotte, P.A.18
Marsh, K.C.19
Moskey, M.D.20
Pease, L.J.21
Stewart, K.D.22
Stoll, V.S.23
Tapang, P.24
Wishart, N.25
Davidsen, S.K.26
Michaelides, M.R.27
more..
-
51
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer, 2008, 8(8), 592-603.
-
(2008)
Nat. Rev. Cancer
, vol.8
, Issue.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
52
-
-
84878325052
-
Beyond anti-vegf: Dual-targeting antiangiogenic and antiproliferative therapy
-
Chen, C. T.; Hung, M. C. Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. Am. J. Transl. Res., 2013, 5(4), 393-403.
-
(2013)
Am. J. Transl. Res.
, vol.5
, Issue.4
, pp. 393-403
-
-
Chen, C.T.1
Hung, M.C.2
-
53
-
-
77957065782
-
Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer
-
Wang, B.; Rosano, J. M.; Cheheltani, R.; Achary, M. P.; Kiani, M. F. Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. Expert Opin. Drug Deliv., 2010, 7(10), 1159-1173.
-
(2010)
Expert Opin. Drug Deliv.
, vol.7
, Issue.10
, pp. 1159-1173
-
-
Wang, B.1
Rosano, J.M.2
Cheheltani, R.3
Achary, M.P.4
Kiani, M.F.5
-
54
-
-
84872197632
-
Tumor cellderived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-vegf drugs
-
Deli Hedlund, E. M.;Yang, X.;Zhang, Y.;Yang, Y.;Shibuya, M.;Zhong, W.;Sun, B.;Liu, Y.;Hosaka, K; Cao, Y. v. Tumor cellderived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc. Natl. Acad. Sci. U S A, 2013, 110(2), 654-659.
-
(2013)
Proc. Natl. Acad. Sci. U S A
, vol.110
, Issue.2
, pp. 654-659
-
-
Deli Hedlund, E.M.1
Yang, X.2
Zhang, Y.3
Yang, Y.4
Shibuya, M.5
Zhong, W.6
Sun, B.7
Liu, Y.8
Hosaka, K.9
Cao, Y.V.10
-
56
-
-
84893578173
-
-
US 20060281678, December 14
-
Lee, Je-Ho; Lee, Seung-Hoo. Novel inhibitor of angiogenesis, tumor progression, and metastasis targeting Ras signalling pathway. US 20060281678, December 14, 2006.
-
(2006)
Novel Inhibitor of Angiogenesis, Tumor Progression, and Metastasis Targeting Ras Signalling Pathway.
-
-
Lee, J.-H.1
Lee, S.-H.2
-
57
-
-
84863021288
-
Plumbagin inhibits tumour angiogenesis and tumour growth through the ras signalling pathway following activation of the vegf receptor-2
-
Lai, L.; Liu, J.; Zhai, D.; Lin, Q.; He, L.; Dong, Y. ; Zhang, J.; Lu, B. ; Chen, Y. ; Yi, Z. ; Liu, M. Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2. Br. J. Pharmacol., 2012, 165(4b), 1084-1096.
-
(2012)
Br. J. Pharmacol.
, vol.165
, Issue.4 B
, pp. 1084-1096
-
-
Lai, L.1
Liu, J.2
Zhai, D.3
Lin, Q.4
He, L.5
Dong, Y.6
Zhang, J.7
Lu, B.8
Chen, Y.9
Yi, Z.10
Liu, M.11
-
58
-
-
33645648696
-
Lack of effect of ketoconazole-mediated cyp3a inhibition on sorafenib clinical pharmacokinetics
-
Lathia, C.; Lettieri, J.; Cihon, F.; Gallentine, M.; Radtke, M.; Sundaresan, P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother. Pharmacol., 2006, 57(5), 685-692.
-
(2006)
Cancer Chemother. Pharmacol.
, vol.57
, Issue.5
, pp. 685-692
-
-
Lathia, C.1
Lettieri, J.2
Cihon, F.3
Gallentine, M.4
Radtke, M.5
Sundaresan, P.6
-
59
-
-
84863814724
-
Vemurafenib in patients with braf v600e mutation-positive advanced melanoma
-
Ravnan, M. C.; Matalka, M. S. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin. Ther., 2012, 34(7), 1474-1486.
-
(2012)
Clin. Ther.
, vol.34
, Issue.7
, pp. 1474-1486
-
-
Ravnan, M.C.1
Matalka, M.S.2
-
60
-
-
84872122524
-
Effect of dabrafenib on melanoma cell lines harbouring the braf(v600d/r) mutations
-
Gentilcore, G.; Madonna, G.; Mozzillo, N.; Ribas, A.; Cossu, A.; Palmieri, G.; Ascierto, P. A. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer, 2013, 13, 17.
-
(2013)
BMC Cancer
, vol.13
, pp. 17
-
-
Gentilcore, G.1
Madonna, G.2
Mozzillo, N.3
Ribas, A.4
Cossu, A.5
Palmieri, G.6
Ascierto, P.A.7
-
61
-
-
84872361487
-
Dabrafenib and its potential for the treatment of metastatic melanoma
-
Menzies A.M.; Long G.V.; Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des. Devel. Ther., 2012, 6, 391-405.
-
(2012)
Drug Des. Devel. Ther.
, vol.6
, pp. 391-405
-
-
Menzies, A.M.1
Long, G.V.2
Murali, R.3
-
62
-
-
7044234484
-
Different signalling pathways regulate vegf and il-8 expression in breast cancer: Implications for therapy
-
Chelouche-Lev, D.; Miller, C. P. ; Tellez, C.; Ruiz, M. ; Bar-Eli, M. ; Price, J. E. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur. J. Cancer, 2004, 40(16), 2509-2518.
-
(2004)
Eur. J. Cancer
, vol.40
, Issue.16
, pp. 2509-2518
-
-
Chelouche-Lev, D.1
Miller, C.P.2
Tellez, C.3
Ruiz, M.4
Bar-Eli, M.5
Price, J.E.6
-
63
-
-
33745859743
-
The braf-mapk signaling pathway is essential for cancer-immune evasion in human melanoma cells
-
Sumimoto, H.; Imabayashi, F.; Iwata, T.; Kawakami, Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med., 2006, 203(7), 1651-1656.
-
(2006)
J. Exp. Med.
, vol.203
, Issue.7
, pp. 1651-1656
-
-
Sumimoto, H.1
Imabayashi, F.2
Iwata, T.3
Kawakami, Y.4
-
64
-
-
67650498443
-
Growth-inhibitory and antiangiogenic activity of the mek inhibitor pd0325901 in malignant melanoma with or without braf mutations
-
Ciuffreda, L.; Del Bufalo, D.; Desideri, M.; Di Sanza, C.; Stoppacciaro, A.; Ricciardi, M. R.; Chiaretti, S.; Tavolaro, S.; Benassi, B.; Bellacosa, A.; Foa, R.; Tafuri, A.; Cognetti, F.; Anichini, A. Zupi, G.; Milella, M. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia, 2009, 11(8), 720-731.
-
(2009)
Neoplasia
, vol.11
, Issue.8
, pp. 720-731
-
-
Ciuffreda, L.1
Del Bufalo, D.2
Desideri, M.3
Di Sanza, C.4
Stoppacciaro, A.5
Ricciardi, M.R.6
Chiaretti, S.7
Tavolaro, S.8
Benassi, B.9
Bellacosa, A.10
Foa, R.11
Tafuri, A.12
Cognetti, F.13
Anichini A. Zupi, G.14
Milella, M.15
-
65
-
-
77951016969
-
A phase ii study of pd-0325901, an oral mek inhibitor, in previously treated patients with advanced nonsmall cell lung cancer
-
Haura, E. B.; Ricart, A. D.; Larson, T. G.; Stella, P. J.; Bazhenova, L.; Miller, V. A.; Cohen, R. B. Eisenberg, P. D.; Selaru, P.; Wilner, K. D.; Gadgeel, S. M. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced nonsmall cell lung cancer. Clin. Cancer Res., 2010, 16(8), 2450-2457.
-
(2010)
Clin. Cancer Res.
, vol.16
, Issue.8
, pp. 2450-2457
-
-
Haura, E.B.1
Ricart, A.D.2
Larson, T.G.3
Stella, P.J.4
Bazhenova, L.5
Miller, V.A.6
Cohen, R.B.7
Eisenberg, P.D.8
Selaru, P.9
Wilner, K.D.10
Gadgeel, S.M.11
-
66
-
-
84855590085
-
Targeting the ras pathway in melanoma
-
Ji, Z.; Flaherty, K. T.; Tsao, H. Targeting the RAS pathway in melanoma. Trends Mol. Med., 2012, 18(1), 27-35.
-
(2012)
Trends Mol. Med.
, vol.18
, Issue.1
, pp. 27-35
-
-
Ji, Z.1
Flaherty, K.T.2
Tsao, H.3
-
67
-
-
77950261074
-
Transcriptional pathway signatures predict mek addiction and response to selumetinib (azd6244)
-
Dry, J. R.; Pavey, S.; Pratilas, C. A.; Harbron, C.; Runswick, S.; Hodgson, D.; Chresta, C.; McCormack, R.; Byrne, N.; Cockerill, M.; Graham, A.; Beran, G.; Cassidy, A.; Haggerty, C.; Brown, H.; Ellison, G.; Dering, J.; Taylor, B. S.; Stark, M.; Bonazzi, V.; Ravishankar, S.; Packer, L.; Xing, F.; Solit, D. B.; Finn, R. S.; Rosen, N.; Hayward, N. K.; French, T.; Smith, P. D. Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244). Cancer Res., 2010, 70(6), 2264-2273.
-
(2010)
Cancer Res.
, vol.70
, Issue.6
, pp. 2264-2273
-
-
Dry, J.R.1
Pavey, S.2
Pratilas, C.A.3
Harbron, C.4
Runswick, S.5
Hodgson, D.6
Chresta, C.7
McCormack, R.8
Byrne, N.9
Cockerill, M.10
Graham, A.11
Beran, G.12
Cassidy, A.13
Haggerty, C.14
Brown, H.15
Ellison, G.16
Dering, J.17
Taylor, B.S.18
Stark, M.19
Bonazzi, V.20
Ravishankar, S.21
Packer, L.22
Xing, F.23
Solit, D.B.24
Finn, R.S.25
Rosen, N.26
Hayward, N.K.27
French, T.28
Smith, P.D.29
more..
-
68
-
-
70449535638
-
Detection of braf mutations in the tumour and serum of patients enrolled in the azd6244 (arry-142886) advanced melanoma phase ii study
-
Board, R. E.; Ellison, G.; Orr, M. C.; Kemsley, K. R.; McWalter, G.; Blockley, L. Y.; Dearden, S. P.; Morris, C.; Ranson, M.; Cantarini, M. V.; Dive, C.; Hughes, A. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br. J. Cancer, 2009, 101(10), 1724-1730.
-
(2009)
Br. J. Cancer
, vol.101
, Issue.10
, pp. 1724-1730
-
-
Board, R.E.1
Ellison, G.2
Orr, M.C.3
Kemsley, K.R.4
McWalter, G.5
Blockley, L.Y.6
Dearden, S.P.7
Morris, C.8
Ranson, M.9
Cantarini, M.V.10
Dive, C.11
Hughes, A.12
-
69
-
-
79952261716
-
Gsk1120212 (jtp-74057) is an inhibitor of mek activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition
-
Gilmartin, A. G.; Bleam, M. R.; Groy, A.; Moss, K. G.; Minthorn, E. A.; Kulkarni, S. G.; Rominger, C. M.; Erskine, S.; Fisher, K. E.; Yang, J.; Zappacosta, F.; Annan, R.; Sutton, D.; Laquerre, S. G. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res., 2011, 17(5), 989-1000.
-
(2011)
Clin. Cancer Res.
, vol.17
, Issue.5
, pp. 989-1000
-
-
Gilmartin, A.G.1
Bleam, M.R.2
Groy, A.3
Moss, K.G.4
Minthorn, E.A.5
Kulkarni, S.G.6
Rominger, C.M.7
Erskine, S.8
Fisher, K.E.9
Yang, J.10
Zappacosta, F.11
Annan, R.12
Sutton, D.13
Laquerre, S.G.14
-
70
-
-
84893531063
-
-
American Society of Clinical Oncology (ASCO). 2012 ASCO Annual Meeting: METRIC phase III study: Efficacy of Trametinib (T), a Potent and Selective MEK Inhibitor (MEKi), In Progressionfree Survival (PFS) and Overall Survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma MM) (Accessed 2012).
-
American Society of Clinical Oncology (ASCO). 2012 ASCO Annual Meeting: METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progressionfree survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). http://www.asco.org/ASCOv2/Meetings/ Abstracts?abstractID=96304&confID=114&vmvie w=abst-detail-view (Accessed 2012).
-
-
-
-
71
-
-
77951678924
-
Blockade of the mek/erk signalling cascade by as703026, a novel selective mek1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
-
Kim, K.; Kong, S. Y.; Fulciniti, M.; Li, X.; Song, W.; Nahar, S.; Burger, P.; Rumizen, M. J.; Podar, K.; Chauhan, D.; Hideshima, T.; Munshi, N. C.; Richardson, P.; Clark, A.; Ogden, J.; Goutopoulos, A.; Rastelli, L.; Anderson, K. C.; Tai, Y. T. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br. J. Haematol., 2010, 149(4), 537-549.
-
(2010)
Br. J. Haematol.
, vol.149
, Issue.4
, pp. 537-549
-
-
Kim, K.1
Kong, S.Y.2
Fulciniti, M.3
Li, X.4
Song, W.5
Nahar, S.6
Burger, P.7
Rumizen, M.J.8
Podar, K.9
Chauhan, D.10
Hideshima, T.11
Munshi, N.C.12
Richardson, P.13
Clark, A.14
Ogden, J.15
Goutopoulos, A.16
Rastelli, L.17
Anderson, K.C.18
Tai, Y.T.19
-
73
-
-
84865113022
-
Usnic acid inhibits breast tumor angiogenesis and growth by suppressing vegfr2-mediated akt and erk1/2 signaling pathways
-
Song, Y.; Dai, F.; Zhai, D.; Dong, Y.; Zhang, J.; Lu, B.; Luo, J.; Liu, M.; Yi, Z. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis, 2012, 15(3), 421-432.
-
(2012)
Angiogenesis
, vol.15
, Issue.3
, pp. 421-432
-
-
Song, Y.1
Dai, F.2
Zhai, D.3
Dong, Y.4
Zhang, J.5
Lu, B.6
Luo, J.7
Liu, M.8
Yi, Z.9
-
74
-
-
84989189813
-
-
WO2012087772. Jun 28
-
Shipps, G.W.; Jr.; Huang; Xiao H.; Deng, Y.Q.; Zhu, L.; Cooper, A.B.; Sun, B.Y; Achab, A. A.; Lo, S.M. Preparation of indazole derivatives as ERK inhibitors useful in the treatment of cancer. WO2012087772. Jun 28, 2012.
-
(2012)
Preparation of Indazole Derivatives as ERK Inhibitors Useful in the treatment of Cancer.
-
-
Shipps Jr., G.W.1
Huang2
Xiao, H.3
Deng, Y.Q.4
Zhu, L.5
Cooper, A.B.6
Sun, B.Y.7
Achab, A.A.8
Lo, S.M.9
-
75
-
-
84893580795
-
-
WO 2008148034, Dec 4
-
Adams, M.E.; Dong, Q.; Kaldor, S.W.; Stafford, J.A.; Wallace, M.B. Preparation of arylaminooxotetrahydroindole derivatives and analogs as MERK-ERK inhibitors. WO 2008148034, Dec 4, 2008.
-
(2008)
Preparation of Arylaminooxotetrahydroindole Derivatives and Analogs As MERK-ERK Inhibitors.
-
-
Adams, M.E.1
Dong, Q.2
Kaldor, S.W.3
Stafford, J.A.4
Wallace, M.B.5
-
76
-
-
84893523147
-
-
WO 2008079814 Jul 3
-
Dong, Qing; Gong, Xianchang; Kaldor, Stephen W.; Kanouni, Toufike; Scorah, Nicholas; Wallace, Michael B.; Zhou, Feng, Preparation of phenylamino pyridopyrimidinediones as MAPK/ERK kinase inhibitors. WO 2008079814, Jul 3, 2008.
-
(2008)
Preparation of Phenylamino Pyridopyrimidinediones as MAPK/ERK Kinase Inhibitors
-
-
Qing, D.1
Xianchang, G.2
Kaldor Stephen, W.3
Toufike, K.4
Nicholas, S.5
Wallace Michael, B.6
Feng, Z.7
-
78
-
-
79955534639
-
Mir-21 induced angiogenesis through akt and erk activation and hif-1alpha expression
-
Liu, L. Z.; Li, C.; Chen, Q.; Jing, Y.; Carpenter, R.; Jiang, Y.; Kung, H. F.; Lai, L.; Jiang, B. H. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One, 2011, 6(4), e19139.
-
(2011)
PLoS One
, vol.6
, Issue.4
-
-
Liu, L.Z.1
Li, C.2
Chen, Q.3
Jing, Y.4
Carpenter, R.5
Jiang, Y.6
Kung, H.F.7
Lai, L.8
Jiang, B.H.9
-
79
-
-
0032515047
-
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/akt signal transduction pathway. Requirement for flk-1/kdr activation
-
Gerber, H. P.; McMurtrey, A.; Kowalski, J.; Yan, M.; Keyt, B. A.; Dixit, V.; Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem., 1998, 273(46), 30336-30343.
-
(1998)
J. Biol. Chem.
, vol.273
, Issue.46
, pp. 30336-30343
-
-
Gerber, H.P.1
McMurtrey, A.2
Kowalski, J.3
Yan, M.4
Keyt, B.A.5
Dixit, V.6
Ferrara, N.7
-
80
-
-
71549119169
-
Wortmannin potentiates roscovitine-induced growth inhibition in human solid tumor cells by repressing pi3k/akt pathway
-
Zhang, F.; Zhang, T.; Jiang, T.; Zhang, R.; Teng, Z. H.; Li, C.; Gu, Z. P.; Mei, Q. Wortmannin potentiates roscovitine-induced growth inhibition in human solid tumor cells by repressing PI3K/Akt pathway. Cancer Lett., 2009, 286(2), 232-239.
-
(2009)
Cancer Lett.
, vol.286
, Issue.2
, pp. 232-239
-
-
Zhang, F.1
Zhang, T.2
Jiang, T.3
Zhang, R.4
Teng, Z.H.5
Li, C.6
Gu, Z.P.7
Mei, Q.8
-
81
-
-
0142227019
-
Targeting the pi3k-akt pathway in human cancer: Rationale and promise
-
Luo, J.; Manning, B. D.; Cantley, L. C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell., 2003, 4(4), 257-262.
-
(2003)
Cancer Cell.
, vol.4
, Issue.4
, pp. 257-262
-
-
Luo, J.1
Manning, B.D.2
Cantley, L.C.3
-
82
-
-
33746800144
-
Pathological angiogenesis is induced by sustained akt signaling and inhibited by rapamycin
-
Phung, T. L.; Ziv, K.; Dabydeen, D.; Eyiah-Mensah, G.; Riveros, M.; Perruzzi, C.; Sun, J.; Monahan-Earley, R. A.; Shiojima, I.; Nagy, J. A.; Lin, M. I.; Walsh, K.; Dvorak, A. M.; Briscoe, D. M. Neeman, M.; Sessa, W. C.; Dvorak, H. F.; Benjamin, L. E. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell., 2006, 10(2), 159-170.
-
(2006)
Cancer Cell.
, vol.10
, Issue.2
, pp. 159-170
-
-
Phung, T.L.1
Ziv, K.2
Dabydeen, D.3
Eyiah-Mensah, G.4
Riveros, M.5
Perruzzi, C.6
Sun, J.7
Monahan-Earley, R.A.8
Shiojima, I.9
Nagy, J.A.10
Lin, M.I.11
Walsh, K.12
Dvorak, A.M.13
Briscoe, D.M.14
Neeman, M.15
Sessa, W.C.16
Dvorak, H.F.17
Benjamin, L.E.18
-
83
-
-
84866313204
-
Zebrafish lead the way in control of vascular permeability
-
Arbiser, J. L. Zebrafish lead the way in control of vascular permeability. Blood, 2012, 120(11), 2162-2164.
-
(2012)
Blood
, vol.120
, Issue.11
, pp. 2162-2164
-
-
Arbiser, J.L.1
-
84
-
-
0025201019
-
Selective inhibition of receptor-coupled phospholipase c-dependent processes in human platelets and polymorphonuclear neutrophils
-
Bleasdale, J. E.; Thakur, N. R.; Gremban, R. S.; Bundy, G. L.; Fitzpatrick, F. A.; Smith, R. J.; Bunting, S. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J. Pharmacol. Exp. Ther., 1990, 255(2), 756-768.
-
(1990)
J. Pharmacol. Exp. Ther.
, vol.255
, Issue.2
, pp. 756-768
-
-
Bleasdale, J.E.1
Thakur, N.R.2
Gremban, R.S.3
Bundy, G.L.4
Fitzpatrick, F.A.5
Smith, R.J.6
Bunting, S.7
-
85
-
-
79955943879
-
Vegf-induced retinal angiogenic signaling is critically dependent on ca (2)(+) signaling by ca(2)(+)/calmodulin-dependent protein kinase ii
-
Banumathi, E.; O'Connor, A.; Gurunathan, S.; Simpson, D. A.; McGeown, J. G.; Curtis, T. M. VEGF-induced retinal angiogenic signaling is critically dependent on Ca(2)(+) signaling by Ca(2)(+)/calmodulin-dependent protein kinase II. Invest. Ophthalmol. Vis. Sci., 2011, 52(6), 3103-3111.
-
(2011)
Invest. Ophthalmol. Vis. Sci.
, vol.52
, Issue.6
, pp. 3103-3111
-
-
Banumathi, E.1
O'Connor, A.2
Gurunathan, S.3
Simpson, D.A.4
McGeown, J.G.5
Curtis, T.M.6
-
86
-
-
33744794029
-
Vegf-e activates endothelial nitric oxide synthase to induce angiogenesis via cgmp and pkg-independent pathways
-
Cudmore, M.; Ahmad, S.; Al-Ani, B.; Hewett, P.; Ahmed, S.; Ahmed, A. VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways. Biochem. Biophys. Res. Commun., 2006, 345(4), 1275-1282.
-
(2006)
Biochem. Biophys. Res. Commun.
, vol.345
, Issue.4
, pp. 1275-1282
-
-
Cudmore, M.1
Ahmad, S.2
Al-Ani, B.3
Hewett, P.4
Ahmed, S.5
Ahmed, A.6
-
87
-
-
85037067799
-
In silico identification of bim-1 (2-methyl-1h-indol-3-yl) as a potential therapeutic agent against elevated protein kinase c beta associated diseases
-
Umar, S.; Nayab, N.; Yasir, W.; Nazia, C.; Bhatti, H. T.; Urooj, S.; Waheed, H.; Ashraf, M.; Khan Naizi, U.H. In silico identification of BIM-1 (2-methyl-1H-indol-3-yl) as a potential therapeutic agent against elevated protein kinase C beta associated diseases. Afr. J. Biotechnol., 2012, 11(19), 4434-4441.
-
(2012)
Afr. J. Biotechnol.
, vol.11
, Issue.19
, pp. 4434-4441
-
-
Umar, S.1
Nayab, N.2
Yasir, W.3
Nazia, C.4
Bhatti, H.T.5
Urooj, S.6
Waheed, H.7
Ashraf, M.8
Khan Naizi, U.H.9
-
88
-
-
24644488646
-
Crystal structure of the catalytic domain of human atypical protein kinase c-iota reveals interaction mode of phosphorylation site in turn motif
-
Messerschmidt, A.; Macieira, S.; Velarde, M.; Badeker, M.; Benda, C.; Jestel, A.; Brandstetter, H.; Neuefeind, T.; Blaesse, M. Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. J. Mol. Biol., 2005, 352(4), 918-931.
-
(2005)
J. Mol. Biol.
, vol.352
, Issue.4
, pp. 918-931
-
-
Messerschmidt, A.1
Macieira, S.2
Velarde, M.3
Badeker, M.4
Benda, C.5
Jestel, A.6
Brandstetter, H.7
Neuefeind, T.8
Blaesse, M.9
-
89
-
-
33751570046
-
Structure of the catalytic domain of human protein kinase c beta ii complexed with a bisindolylmaleimide inhibitor
-
Grodsky, N.; Li, Y.; Bouzida, D.; Love, R.; Jensen, J.; Nodes, B.; Nonomiya, J.; Grant, S. Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor. Biochemistry, 2006, 45(47), 13970-13981.
-
(2006)
Biochemistry
, vol.45
, Issue.47
, pp. 13970-13981
-
-
Grodsky, N.1
Li, Y.2
Bouzida, D.3
Love, R.4
Jensen, J.5
Nodes, B.6
Nonomiya, J.7
Grant, S.8
-
90
-
-
0042490796
-
Vascular endothelial growth factor-b promotes in vivo angiogenesis
-
Silvestre, J. S.; Tamarat, R.; Ebrahimian, T. G.; Le-Roux, A. ; Clergue, M. ; Emmanuel, F. ; Duriez, M. ; Schwartz, B. ; Branellec, D. ; Levy, B. I. Vascular Endothelial Growth Factor-B Promotes In vivo Angiogenesis. Circ. Res., 2003, 93(2), 114-123.
-
(2003)
Circ. Res.
, vol.93
, Issue.2
, pp. 114-123
-
-
Silvestre, J.S.1
Tamarat, R.2
Ebrahimian, T.G.3
Le-Roux, A.4
Clergue, M.5
Emmanuel, F.6
Duriez, M.7
Schwartz, B.8
Branellec, D.9
Levy, B.I.10
-
91
-
-
0343851651
-
Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells
-
Dulak, J.; Jozkowicz, A.; Dembinska-Kiec, A.; Guevara, I.; Zdzienicka, A.; Zmudzinska-Grochot, D.; Florek, I.; Wojtowicz, A.; Szuba, A.; Cooke, J. P. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2000, 20(3), 659-666.
-
(2000)
Arterioscler. Thromb. Vasc. Biol.
, vol.20
, Issue.3
, pp. 659-666
-
-
Dulak, J.1
Jozkowicz, A.2
Dembinska-Kiec, A.3
Guevara, I.4
Zdzienicka, A.5
Zmudzinska-Grochot, D.6
Florek, I.7
Wojtowicz, A.8
Szuba, A.9
Cooke, J.P.10
-
92
-
-
33646145320
-
Angiotensin ii stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes
-
Kang, Y. S.; Park, Y. G.; Kim, B. K.; Han, S. Y.; Jee, Y. H.; Han, K. H.; Lee, M. H.; Song, H. K.; Cha, D. R.; Kang, S. W.; Han, D. S. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J. Mol. Endocrinol., 2006, 36(2), 377-388.
-
(2006)
J. Mol. Endocrinol.
, vol.36
, Issue.2
, pp. 377-388
-
-
Kang, Y.S.1
Park, Y.G.2
Kim, B.K.3
Han, S.Y.4
Jee, Y.H.5
Han, K.H.6
Lee, M.H.7
Song, H.K.8
Cha, D.R.9
Kang, S.W.10
Han, D.S.11
-
93
-
-
84861868696
-
Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer
-
Straume, O.; Shimamura, T.; Lampa, M. J.; Carretero, J.; Oyan, A. M.; Jia, D.; Borgman, C. L.; Soucheray, M.; Downing, S. R.; Short, S. M.; Kang, S. Y.; Wang, S.; Chen, L.; Collett, K.; Bachmann, I.; Wong, K. K.; Shapiro, G. I.; Kalland, K. H.; Folkman, J.; Watnick, R. S.; Akslen, L. A.; Naumov, G. N. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc. Natl. Acad. Sci. U S A, 2012, 109(22), 8699-8704.
-
(2012)
Proc. Natl. Acad. Sci. U S A
, vol.109
, Issue.22
, pp. 8699-8704
-
-
Straume, O.1
Shimamura, T.2
Lampa, M.J.3
Carretero, J.4
Oyan, A.M.5
Jia, D.6
Borgman, C.L.7
Soucheray, M.8
Downing, S.R.9
Short, S.M.10
Kang, S.Y.11
Wang, S.12
Chen, L.13
Collett, K.14
Bachmann, I.15
Wong, K.K.16
Shapiro, G.I.17
Kalland, K.H.18
Folkman, J.19
Watnick, R.S.20
Akslen, L.A.21
Naumov, G.N.22
more..
-
94
-
-
84868087634
-
Anti-angiogenic effects of thioridazine involving the fak-mtor pathway
-
Byun, H. J.; Lee, J. H.; Kim, B. R.; Kang, S.; Dong, S. M.; Park, M. S.; Lee, S. H.; Park, S. H.; Rho, S. B. Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway. Microvasc. Res., 2012, 84(3), 227-234.
-
(2012)
Microvasc. Res.
, vol.84
, Issue.3
, pp. 227-234
-
-
Byun, H.J.1
Lee, J.H.2
Kim, B.R.3
Kang, S.4
Dong, S.M.5
Park, M.S.6
Lee, S.H.7
Park, S.H.8
Rho, S.B.9
|